Koninklijke Philips N.V. (NYSE:PHG)
Koninklijke Philips N.V. (NYSE:PHG) represented a move of -3.47 percent or $0.67 per share and closed its previous day trading session at $35.1. 2.19 Million Shares were traded in the last trading session with an Average Volume of 1.01 Million Shares. The stock currently has a Market Capitalization of 33.79 Billion.
Koninklijke Philips Electronics N.V. is the parent company of Philips, a widely diversified multinational group of electronic and electrical products, systems and equipment, as well as information technology services.
The stock traded between $35.09 and $46.67 over 1-Year time period showing its price to sales ratio of 1.67. Koninklijke Philips N.V. (NYSE:PHG) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-19.19 and 200-Day Simple Moving Average of $-15.71. Its Price to Free Cash Flow is 0 and Price to Book of 2.41.
Analyst’s recommended the stock as 1 where 1 represents Strong Buy and 5 represents Sell.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
In the last trading session, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) added its value by -7.56% closing at the price of $11.98. The stock currently has market capitalization of 1.08 Billion, with average volume of 2.59 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is showing beta of 1.98. This particular value of beta suggests that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has historically moved 198% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is at $-0.68.
The stock currently has RSI of 31.83. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) topped its 52-week high price of $22.39 on 09/06/18 and 52-Week Low Price of $ 3.01 on 12/13/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.19% and monthly volatility of 9.00% respectively.